Achieving Equitable Access to Medicines and Health Services: A COVID-19-time Recalled Matter.

COVID-19 Equity Health Inequity Medicine Pharmaceutical Policy

Journal

Iranian journal of pharmaceutical research : IJPR
ISSN: 1735-0328
Titre abrégé: Iran J Pharm Res
Pays: Netherlands
ID NLM: 101208407

Informations de publication

Date de publication:
2021
Historique:
entrez: 23 2 2022
pubmed: 24 2 2022
medline: 24 2 2022
Statut: ppublish

Résumé

In the 21

Identifiants

pubmed: 35194459
doi: 10.22037/ijpr.2021.116120.15709
pmc: PMC8842612
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

450-466

Déclaration de conflit d'intérêts

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Références

J Bioeth Inq. 2020 Dec;17(4):703-707
pubmed: 32840837
Glob Health Promot. 2021 Jun;28(2):7-16
pubmed: 33761795
J Gen Intern Med. 2017 May;32(5):572-575
pubmed: 27798781
Int J Health Serv. 2021 Oct;51(4):570-572
pubmed: 34106781
JAMA Oncol. 2019 Oct 1;5(10):e191870
pubmed: 31415071
PLoS Med. 2011 Nov;8(11):e1001115
pubmed: 22069378
JAMA Netw Open. 2020 Oct 1;3(10):e2021767
pubmed: 33006616
Int J Health Policy Manag. 2018 Jan 20;7(5):374-393
pubmed: 29764102
Daru. 2020 Dec;28(2):799-805
pubmed: 32617864
Am J Trop Med Hyg. 2020 Jun;102(6):1149-1150
pubmed: 32297589
Rev Panam Salud Publica. 2020 May 29;44:e70
pubmed: 32523608
Arch Iran Med. 2020 Apr 01;23(4Suppl1):S43-S48
pubmed: 32349508
Med J Islam Repub Iran. 2021 Apr 19;35:51
pubmed: 34268239
Ethics Med Public Health. 2021 Jun;17:100653
pubmed: 33758775
Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):475-478
pubmed: 32890537
Health Promot J Austr. 2021 Jan;32(1):3-5
pubmed: 33448086
J Oncol Pract. 2018 Jan;14(1):e1-e10
pubmed: 29099678
Daru. 2019 Jun;27(1):243-254
pubmed: 31055777
Lancet. 2019 Nov 2;394(10209):1600-1601
pubmed: 31519433
Int J Public Health. 2020 Jun;65(5):521-523
pubmed: 32462311

Auteurs

Taraneh Mousavi (T)

Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Shekoufeh Nikfar (S)

Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group, Pharmaceutical Sciences Research Center (PSRC), and the Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Abdollahi (M)

Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Classifications MeSH